中文名 | CS-2759 |
英文名 | Anavex 2-73 |
别名 | 化合物ANAVEX 2-73 1-(2,2-二苯基四氢呋喃-3-基)-N,N-二甲基甲胺盐酸盐 |
英文别名 | AE37 AE-37 AE 37 CS-2759 AVEX73 AVEX-73 AVEX 73 ANAVEX273 ANAVEX 273 ANAVEX-273 Anavex 2-73 ANAVEX 2 73 ANAVEX-2-73 BLARCAMESINE Anavex2-73 HCl AE-37 HYDROCHLORIDE AVex-73 hydrochloride BLARCAMESINE HYDROCHLORIDE, AVEX-73 HYDROCHLORIDE, AE-37 HYDROCHLORIDE |
CAS | 195615-84-0 |
化学式 | C19H24ClNO |
分子量 | 317.86 |
熔点 | 165 - 168°C |
溶解度 | DMSO (微溶) 、甲醇 (微溶) |
存储条件 | -20°C Freezer, Under inert atmosphere |
外观 | 固体 |
颜色 | White to Off-White |
体内研究 | The pre-administration of Blarcamesine (ANAVEX2-73) leads to a dose-dependent attenuation of the scopolamine induced alternation deficit, significant at 1 and 3 mg/kg. The pre-treatment with Blarcamesine hydrochloride attenuates the impairments of step-through latency, dose dependently and significantly at doses higher than 0.3 mg/kg. The Blarcamesine hydrochloride treatment dose-dependently blocks the recognition memory deficit, with a significant effect measured at 1 mg/kg. One day after injections, the significant Aβ 25-35 -induced decrease in Akt phosphorylation is significantly attenuated by Blarcamesine hydrochloride at 0.1 and 1 mg/kg dose. Seven days after injections, Blarcamesine hydrochloride attenuates the decrease in Ser 9 phosphorylation induced by the peptide at 0.3 and 1 mg/kg. The Blarcamesine hydrochloride treatment dose-dependently prevents the Aβ 25-35 -induced increase in Aβ 1-42 content, with a significant effect at the highest dose tested. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.146 ml | 15.731 ml | 31.461 ml |
5 mM | 0.629 ml | 3.146 ml | 6.292 ml |
10 mM | 0.315 ml | 1.573 ml | 3.146 ml |
5 mM | 0.063 ml | 0.315 ml | 0.629 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!